Oncology
Partner With Us
Advertisement
From the Journals

ASCENT-03 Study Presented by Sara Tolaney, MD, MPH

Dr. Sara Tolaney details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.

Dana-Farber

Dr. Sara Tolaney details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.